Factor This Power Engineering
Live Events
DTECH® Events
POWERGEN™
INFOCAST Events
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
POWERGEN™
INFOCAST Events
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Gossamer Bio, Inc. - Common Stock
(NQ:
GOSS
)
0.1605
-0.0051 (-3.08%)
Streaming Delayed Price
Updated: 3:21 PM EDT, Jun 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gossamer Bio, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Gossamer Bio (GOSS) Q1 2026 Earnings Transcript
↗
May 27, 2026
Gossamer Bio (GOSS) Q1 2026 Earnings Transcript
Via
The Motley Fool
These stocks are moving in today's session
↗
May 18, 2026
Via
Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session.
↗
May 18, 2026
Via
Chartmill
Exploring Gossamer Bio's Earnings Expectations
↗
May 14, 2025
Via
Benzinga
Which stocks are gapping on Monday?
↗
May 18, 2026
Via
Chartmill
Gossamer Bio Q1 Earnings Call Highlights
↗
May 18, 2026
Gossamer Bio (NASDAQ:GOSS) said it is moving ahead with plans to seek U.S. approval for seralutinib in pulmonary arterial hypertension, outlining a September 2026 target for a New Drug Application...
Via
MarketBeat
Topics
Earnings
These stocks are the most active in today's session
↗
February 25, 2026
Via
Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
↗
February 25, 2026
Via
Chartmill
In today's session, these stocks are experiencing unusual volume.
↗
February 24, 2026
Via
Chartmill
Check out the stocks that are attracting the most attention and driving market activity.
↗
February 23, 2026
Via
Chartmill
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash?
↗
February 23, 2026
Gossamer Bio’s seralutinib did not achieve the predefined statistical bar for its main goal in the phase 3 PROSERA trial.
Via
Stocktwits
These stocks are gapping in today's session
↗
February 23, 2026
Via
Chartmill
This Saia Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
↗
September 10, 2025
Via
Benzinga
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
July 14, 2025
Via
Benzinga
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream
↗
June 13, 2025
Via
Stocktwits
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
December 12, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
October 02, 2024
Via
Benzinga
GOSS Stock Earnings: Gossamer Bio Misses EPS, Misses Revenue for Q2 2024
↗
August 12, 2024
GOSS stock results show that Gossamer Bio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Earnings Scheduled For May 15, 2025
↗
May 15, 2025
Via
Benzinga
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
↗
June 25, 2024
Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary arterial hypertension. Seralutinib shows potential in underserved markets.
Via
Benzinga
Gossamer Bio And 2 Other Stocks Under $2 Insiders Are Buying
↗
June 25, 2024
Via
Benzinga
Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
June 21, 2024
Via
Benzinga
The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street
↗
June 13, 2024
Taking a small position in these penny stocks today could have you sitting on a sizable gain by the time Wall Street starts to pile in.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
June 11, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
May 13, 2024
Via
Benzinga
GOSS Stock Earnings: Gossamer Bio Misses EPS for Q1 2024
↗
May 07, 2024
GOSS stock results show that Gossamer Bio missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide
↗
May 06, 2024
Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
April 25, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
April 05, 2024
Via
Benzinga
Goldman Sachs Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know
↗
March 06, 2024
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
